Trinity Biotech Accelerates Transformation and Growth

Trinity Biotech (TRIB) has released an update.

Trinity Biotech plc has unveiled its fourth quarter and full year 2023 financial outcomes alongside major business advancements, including a comprehensive plan to enhance financial performance through operational consolidation, cost reductions, and a strategic move to outsource manufacturing. The company is targeting a significant increase in EBITDASO by mid-2025, based solely on existing business growth, excluding new biosensor contributions. Trinity Biotech has also acquired biosensor assets, aiming to develop a groundbreaking continuous glucose monitor that promises affordability and improved data capture, with a strong focus on expanding their wearable biosensor business.

For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.